ADT Does Not Raise Risk of Heart Attacks In Men With No History Of Heart Disease
Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint
MDV3100 Improves Survival, Reduces Death Risk by 37%
Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication
Elevated Baseline Glucose Levels Associated With Higher Cancer Risk
Oncotype DX Cancer Test Can Predict Recurrence
Signet Cell A Rising Trend In Patients Under Age 40
FIT More Effective Than gFOBT In All Colonoscopy Capacities
Tumor Treating Fields Therapy Increased Three-Year Survival
Only 20 Percent Of At-Risk Patients Are Screened For HBV Before Therapy
New Algorithm Completes Scan Three Times Faster Than Before
Survivorship Studies Unfocused As Total Research Increases
Trials Approved by NCI CTEP Last Month
Agency Approves HPV Test That Detects 14 High-Risk Strains
Alimta Granted Approval As NSCLC Continuation Therapy
Trending Stories
- Supreme Court removes “Chevron deference,” threatening drug regulation, health coverage, delivery of cancer care
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Elizabeth Comen joins NYU Langone Health’s Perlmutter Cancer Center
- A modest proposal from a former FDA commissioner: Add antidepressants to the nation’s water supply
Warning: This is not a public health recommendation. Do not implement. - At Lung SPORE Workshop, experts reflect on the significance of discovery of EGFR mutations two decades ago
- The early days of EGFR: Herbst, Haber, Meyerson, Pao, Sequist present at Yale SPORE workshop